Abstract
Introduction
Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitides (AAV) are systemic necrotizing vasculitides characterized by the presence of circulating ANCA in about 90% of patients [1] . AAV include granulomatosis with polyangiitis, microscopic polyangiitis, eosinophilic granulomatosis with polyangiitis and renal limited vasculitis [2] . ANCA-associated glomerulonephritis (ANCA GN) is present in more than 50% of AAV patients at diagnosis and about 70-85% of these patients develop renal vasculitis during their disease course [3] . Severe renal dysfunction portends a poor prognosis and causes end-stage renal disease (ESRD) or death in 50% of patients at 5 years [3, 4] . Recent advances in therapy have transformed AAV from a fatal disease to one with a relapsing course, but substantial treatment-related morbidity exists. Data from the European vasculitis study group demonstrate that the mortality is highest in the first year with most of them being attributable to infection [5] . Prognosis is an important issue in renal vasculitis where both the disease and therapies may lead to significant morbidity and mortality.
Several histopathologic studies have demonstrated that the combination of glomerular filtration rate (GFR) at baseline and renal histology is a better predictor of renal outcome than GFR alone [6] [7] [8] [9] [10] [11] [12] . In 2010, an international working group of renal pathologists proposed a new classification for ANCA GN based on glomerular pathology to assess its predictive value for renal survival and validated it using patient data [13] . The classification system categorized ANCA GN into 4 classes based on glomerular pathology: focal, crescentic, mixed, and sclerotic. Subsequent to this study, a number of validation studies in several cohorts in Europe, Asia, and the United States confirmed the predictive value of this classification for renal survival in focal and sclerotic class and mixed results in crescentic and mixed class [14] . The sclerotic class ANCA GN had the worst short-and long-term renal survival. Following treatment, the 1-and 5-year renal survival in these patients is about 50% suggesting that renal function can be stabilized with treatment in a significant number of patients. There is lack of data on prognostic markers to identify patients who progress to ESRD where immunosuppression is likely to cause more harm than benefits. This study aims to determine prognostic markers of renal outcome among patients with sclerotic class ANCA GN.
Methods
Study patients were recruited from 5 centers worldwide (the United States, the United Kingdom, the Czech Republic, Ireland, and China). Patients were eligible for study entry if they had ANCA-associated GN clinically as well as biopsy-proven sclerotic class ANCA GN, defined as > 50% of glomeruli on biopsy sample demonstrating global sclerosis. Biochemical, clinical measurements, and details of immunosuppressive therapy were recorded with time origin being the time of kidney biopsy. The number of normal glomeruli, glomeruli with cellular crescents and fibrocellular crescents was recorded for each biopsy by review of paper reports and slides. The degree of interstitial fibrosis (IF) and tubular atrophy was graded mild (< 25%), moderate (25-50%), or severe (> 50%) depending on extent of involvement. Patients with missing data regarding diagnosis of ESRD, estimated GFR (eGFR), both at baseline and at 12 months, were excluded from analysis. Treatment response was defined clinically by stabilization or improvement of serum creatinine with resolution of hematuria and absence of signs of extra-renal vasculitis. Relapse was defined by biopsy-proven pauci-immune GN or an increase in vasculitis activity requiring an increase in immunosuppressive drug therapy. The study was approved by the Institutional review board at each center. Notably, because there are no standardized treatment guidelines for sclerotic class ANCA vasculitis, patients observed in this study underwent a number of different immunosuppression regimens as will be explained in detail below. The study outcomes were 12-month eGFR based on the equation derived by Levey and colleagues based on the Modification of Diet in Renal Disease Study and ESRD defined as te need for initiation of renal replacement therapy in the form of dialysis or transplant [15] . Estimated GFR at 12 months was modeled as a function of various predictors using both simple and multiple linear regression analyses. The hazard of ESRD was modeled using Cox proportional hazards regression in both univariable and multivariable analyses. The Breslow method was used for ties. The outcome of ESRD-free survival was further demonstrated with Kaplan-Meier survival curves. The degree of tubular atrophy and IF was categorized as mild, moderate, or severe on biopsy. All analyses were run using Stata version 15 (Stata Corporation, College Station, TX, USA).
Results
Of the 50 patients who met the inclusion criteria, 92% were Caucasian and 60% were male with a median overall age at biopsy of 63.5 (interquartile range [IQR] 50-73) years. Eight patients (16%) were positive for PR3 and 41 (82%) were positive for MPO. The remaining patients were ANCA negative by serolgies but with a biopsy showing pauci-immune vasculitis with evidence of sclerosis. Thirty-six patients (72%) had renal limited AAV and the remaining patients had evidence of extra-renal disease. The median eGFR at entry was 14.5 (IQR 9-19) mL/ min/1.73 m 2 . Baseline characteristics can be found in Table 1 . Kidney biopsies obtained a median of 20 (IQR 15-34) glomeruli, of which 23 specimens (46%) had some evidence of fibrocellular crescents, while 28 (56%) had some evidence of fibrous crescent formation. Only 2 biopsies had less than 10 glomeruli for analysis. The median percent sclerosed glomeruli in samples was 67 (IQR 59-75).
In total, 48 biopsy samples (96%) showed moderate to severe IF. Only 20 patients (40%) had any normal-appearing glomeruli on biopsy, and of these, over half (12 patients) had only 1-2 normal glomeruli visualized. While 32 specimens (64%) had at least one cellular crescent, 11 (22%) had 3 or more. Out of 32 patients with A total of 48 patients (96%) were treated with immunosuppressive medications. Eight patients also received plasmapheresis. Thirty-five patients (70%) received pulse intravenous (IV) methylprednisolone, while 32 (64%) received cyclophosphamide. Of the 32 patients treated with cyclophosphamide, 24 (75%) received IV cyclophosphamide, while the remaining 8 received the oral formulation. Eleven (22%) patients received IV rituximab and 4 patients received both cyclophosphamide and rituximab (8%; Table 1 ). Of the 48 patients treated with immunosuppressive therapy with or without plasmapheresis, 1 patient never achieved treatment response despite treatment with cyclophosphamide and rituximab. Of the 2 patients who did not receive any immunosuppression, both had renal-limited disease and progressed to ESRD.
Outcomes were observed in the clinical setting with follow-up times varying by center, but on average 2-3 months between visits. Overall, treatment response was achieved in nearly all patients undergoing treatment (n = 47/48, 98%), which occurred in the first 4-6 months of followup. Out of the 48 who received immunosuppression, 34 patients received maintenance immunosuppression. Of those patients who achieved initial treatment response, 9 (18.3%) experienced relapse, 5 of which involved the kidney. Ten patients died during follow-up with 6 of them in the first year of diagnosis. Of the 6 early deaths, 3 were infection related, 1 patient died after complications of femoral neck fracture, and the cause of death was unknown in 2 patients. One of the 6 patients was HD dependent at study entry.
For our analysis, kidney function at 12 months was first modeled by simple linear regression, excluding those 6 patients who died within the first year from analysis (onine suppl. Table 1 ; for all online suppl. material, see www. karger.com/doi/10.1159/000494840). In univariable analysis, entry eGFR was positively associated with eGFR at 12 months (β = 1.16 mL/min/1.73 m 2 ; 95% CI 0.816-1.51). The degree of tubular atrophy was also statistically and significantly associated with 12-month GFR (β = -10.5 mL/min/1.73 m 2 ; 95% CI -18.4 to -2.67). With regard to treatment, there was a statistically significant higher 12-month eGFR in patients who received rituximab (β = 14.0 mL/min/1.73 m 2 ; 95% CI 6.58-21.5), while the use of cyclophosphamide was statistically significantly associated with a lower GFR at 12 months (β = -11.1 mL/ min/1.73m 2 ; 95% CI -18.6 to -3.63). Age and degree of IF were not statistically and significantly associated with eGFR at 12 months, though a higher degree of IF approached clinical significance with a decline in GFR. Further, there was no statistically significant association between 12-month eGFR and gender, ANCA type, or other pathologic features (percentage of normal glomeruli, percentage of cellular crescents). In our multivariable model, further adjusted for use of rituximab and cyclophosphamide, both entry GFR and degree of tubular atrophy remained statistically significant (r 2 = 0.722; Table 2 ).
Among the 38 patients not requiring hemodialysis (HD) at study entry, 15 went on to develop ESRD (39.5%) compared to 11 out of the 12 patients on HD at study entry (91.7%; online suppl. Fig. 1 ). All 38 patients were treated with immunosuppression and even those who eventually progressed to ESRD showed some initial treatment response. In total, 10 of the twelve patients who were HD dependent at study entry received at least some immunosuppression, of which only one had treatment response. The incidence rate of ESRD for those who were on HD at the time of diagnosis was 40.7/100 person-months (95% CI 22.7-73.6). In comparison, for the 38 patients who were not HD-dependent at the start of diagnosis, the incidence rate of ESRD was 5.88/100 person-months (95% CI 3.55-9.76).
ESRD-free, or renal, survival was modeled with Cox proportional hazards regression (Table 3 ; online suppl. Table 2 ). In univariable analysis, there was a statistically significantly increased hazard of progressing to ESRD with lower eGFR at study entry (1.11, 95% CI 1.04-1.19). Similarly, dialysis dependence at study entry was also associated with an increased hazard of ESRD (HR 11.1, 95% CI 4.04-30.7). A higher degree of tubular atrophy was associated with progression to ESRD as well (HR 2.69, 95% CI 1.03-7.01). In a multivariable model including both entry GFR and degree of tubular atrophy, entry-GFR remained statistically and significantly associated, with a lower hazard of ESRD with higher GFR, while the risk of ESRD with increasing tubular atrophy was no longer statistically significant. Tubular atrophy was classified as mild, moderate, or severe and modeled accordingly. Renal survival was visually depicted using Kaplan-Meier graphs showing the differential progression to ESRD by these variables ( Fig. 1, 2 ; online suppl. Fig. 2 ). For the purposes of the Kaplan-Meier graphs, entry GFR was broken up into eGFR < 15, 15-30, and > 30 mL/min/1.73 m 2 .
Discussion
We report the results of the largest series of sclerotic class ANCA GN patients that aimed to ascertain predictors of renal outcome. In this study, baseline GFR and tubular atrophy are predictors of both 1-year GFR and overall renal survival. The study demonstrates that renal recovery is very rare among patients who are dialysis dependent at entry.
This study comprised on predominantly MPO ANCApositive patients. This might directly be related to the inclusion of only sclerotic class ANCA GN in this study and reflects high prevalence of chronic lesions in MPO ANCA patients seen in prior studies [9, 16] . Entry GFR has been shown to be an independent predictor of renal outcome in multiple cohorts [4, 8, 9, [17] [18] [19] and remains the best predictor in this study comprised of sclerotic class ANCA GN. In fact, the correlation of entry GFR with long-term renal outcome is so strong that the prognostic significance of ANCA GN classification disappears when adjusted for entry GFR [19] .
The prognostic value of the ANCA GN classification was strengthened by adding the percent normal glomeruli in the crescentic and mixed ANCA GN [20] or by adding percent crescent in mixed class [19] . Among the histologic predictors of renal outcome, percent normal glomeruli has been demonstrated to predict renal function in previous studies. A correlation between percentage normal glomeruli and renal function has been dem- onstrated in previous studies [6-9, 11, 12, 19] . In patients with crescentic and mixed type ANCA GN, the presence of > 25% normal glomeruli was predictive of improved GFR [20] . The findings in this study are contradictory and this may be related to the overall chronicity score seen in our cohort. Cellular crescents have been shown to respond to immunosuppressive therapy and subsequent improvement in GFR [9] . In mixed class ANCA GN, the presence of less than 20% cellular crescents in the biopsy sample was associated with a lower 1-year GFR by Tanna et al. [19] . In this study, the presence of cellular crescents did not correlate with improved GFR. This may be related to the underlying severe chronic changes in sclerotic class ANCA GN.
This study demonstrates that the degree of tubular atrophy correlated with long-term renal outcome. Historically chronic tubulo-interstitial lesions have been identified as predictors of adverse renal outcome [8, 9, 21, 22] . Adding IF and tubular atrophy to enhance the predictive value of ANCA GN classification has yielded variable results. An association between higher degree of tubular atrophy and worse renal outcome was reported by Quintana et al. [19, 23] In the Berden study and in the Chinese cohort, there was no correlation of IF and tubular atrophy with long-term renal function [13, 24] .
Patients with sclerotic class GN have adverse prognosis with persistently elevated risk of ESRD or death in multiple cohorts [13, 14, 25] . The 1-and 5-year renal survival in validation studies have ranged from 29 to 52% and 29 to 75% [19, 23, 26] . Similar to these studies, we see poor renal and patient survival in our cohort. It may be that in those patients with significant tubular atrophy, and sclerotic class disease, especially if they are dialysisdependent on biopsy, that any treatment would prove fruitless. Future studies are needed to evaluate the influence of treatment, particularly in those patients with significant kidney injury at the start of therapy.
We acknowledge that the study is subject to limitations inherent in a retrospective study. Although, the histopathological scoring was performed by experienced pathologists, inter-observer variation was not assessed. There are insufficient data to explore the association of plasmapheresis and outcomes in sclerotic class ANCA GN, as well as too few observations for any significant adjustment for potential confounders. Further, as only 9 patients experienced relapse over the course of follow-up, there was not sufficient power to model this outcome in any meaningful fashion. The study was enriched with MPO ANCA patients and may not be generalizable to PR3 ANCA patients.
In conclusion, the study demonstrates that renal recovery is rare in patients requiring dialysis at entry despite standard immunosuppression in sclerotic ANCA GN patients. Baseline GFR and tubular atrophy remain as predictors of renal outcome. More information is needed on predictors of treatment response and optimal use of immunosuppression in these patients.
